Develops treatments for PTSD, fibromyalgia, and other central nervous system conditions.
Tonix Pharmaceuticals Holding Corp. operates as a dynamic clinical-stage biopharmaceutical firm dedicated to the discovery, acquisition, development, and licensing of innovative therapeutics and diagnostics aimed at treating and preventing human diseases while alleviating suffering. With a diverse portfolio spanning immunology, rare diseases, infectious diseases, and central nervous system (CNS) disorders, Tonix Pharmaceuticals is at the forefront of medical innovation.
The company's immunology pipeline includes promising biologics targeting conditions such as organ transplant rejection, autoimmunity, and cancer. Notable candidates include TNX-1500, a humanized monoclonal antibody designed to block CD40-ligand, crucial for preventing allograft and xenograft rejection as well as treating autoimmune disorders. Tonix's rare disease portfolio features TNX-2900, developed specifically for Prader-Willi syndrome, addressing critical unmet needs in this patient population.
In the realm of infectious diseases, Tonix Pharmaceuticals is advancing vaccines like TNX-801 for smallpox and monkeypox, alongside TNX-1840 and TNX-1850 as potential COVID-19 vaccines. The company's CNS-focused initiatives include TNX-102 SL, a small molecule drug in mid-Phase 3 trials for fibromyalgia management, TNX-1900 for migraine prevention, and TNX-1300, a biologic targeting cocaine intoxication. Headquartered in Chatham, New Jersey, Tonix Pharmaceuticals continues to drive therapeutic innovation through strategic research, partnerships, and a steadfast commitment to improving global healthcare outcomes.